In this OIS Podcast episode, host Dr. Robert Rothman sits down with Daphne Haim-Langford, PhD, Founder & CEO of Tarsier Pharma, and Ashley Kline, Chief Commercial Officer, to discuss their groundbreaking approach to uveitis treatment.

Tarsier’s lead candidate, TRS01, is a first-in-class bio-inspired therapy designed to control inflammation without raising intraocular pressure, a major complication of steroid treatments. With a unique mechanism of action that modulates macrophages and reduces inflammation, this novel drug has the potential to redefine uveitis and glaucoma care.

In this episode, you’ll learn:

🔹 How Tarsier’s bio-inspired molecule is changing the game in ophthalmology.

🔹 Why steroids, despite being the standard of care, can be problematic for uveitis patients.

🔹 The challenges of scaling manufacturing and securing regulatory approval for novel ophthalmic treatments.

🔹 Insights from Ashley Kline on the commercial strategy for launching Tarsier’s therapy.

🔹 How Dr. Rothman sees this innovation reshaping ophthalmology and glaucoma treatment.

🎧 Tune in to hear how Tarsier Pharma is working to bring a safer, more effective treatment to market! Subscribe to the OIS Podcast today!